
CeriBell, Inc. (NASDAQ:CBLL - Free Report) - Equities researchers at William Blair lowered their Q3 2025 earnings per share (EPS) estimates for shares of CeriBell in a research report issued on Wednesday, August 6th. William Blair analyst B. Vazquez now anticipates that the company will earn ($0.41) per share for the quarter, down from their prior forecast of ($0.38). The consensus estimate for CeriBell's current full-year earnings is ($2.46) per share. William Blair also issued estimates for CeriBell's FY2025 earnings at ($1.56) EPS, Q1 2026 earnings at ($0.37) EPS, Q2 2026 earnings at ($0.34) EPS, Q3 2026 earnings at ($0.35) EPS, Q4 2026 earnings at ($0.36) EPS and FY2026 earnings at ($1.41) EPS.
CeriBell (NASDAQ:CBLL - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.38) earnings per share for the quarter, beating analysts' consensus estimates of ($0.40) by $0.02. CeriBell had a negative net margin of 63.83% and a negative return on equity of 48.42%. The business had revenue of $21.20 million for the quarter, compared to analysts' expectations of $20.52 million.
Separately, BTIG Research began coverage on shares of CeriBell in a report on Tuesday, June 24th. They issued a "buy" rating and a $30.00 price target on the stock. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, CeriBell presently has an average rating of "Buy" and a consensus target price of $32.14.
Check Out Our Latest Report on CeriBell
CeriBell Stock Up 2.6%
CBLL traded up $0.33 during trading on Friday, hitting $12.91. The stock had a trading volume of 629,190 shares, compared to its average volume of 289,622. The company has a market capitalization of $473.28 million and a PE ratio of -4.32. CeriBell has a twelve month low of $10.01 and a twelve month high of $32.75. The company has a debt-to-equity ratio of 0.11, a quick ratio of 16.81 and a current ratio of 13.31. The stock has a 50 day simple moving average of $16.70 and a two-hundred day simple moving average of $18.51.
Insider Buying and Selling at CeriBell
In other news, CEO Xingjuan Chao sold 25,000 shares of the business's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $17.00, for a total transaction of $425,000.00. Following the sale, the chief executive officer directly owned 776,022 shares of the company's stock, valued at $13,192,374. The trade was a 3.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Rebecca B. Robertson sold 20,000 shares of the business's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $17.14, for a total transaction of $342,800.00. Following the sale, the director directly owned 28,675 shares in the company, valued at $491,489.50. This trade represents a 41.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 113,633 shares of company stock worth $1,965,261 over the last ninety days. Corporate insiders own 20.10% of the company's stock.
Institutional Investors Weigh In On CeriBell
Large investors have recently made changes to their positions in the stock. Legal & General Group Plc purchased a new stake in shares of CeriBell during the fourth quarter valued at $32,000. Summit Investment Advisors Inc. purchased a new stake in shares of CeriBell during the fourth quarter valued at $33,000. Tower Research Capital LLC TRC purchased a new stake in shares of CeriBell during the fourth quarter valued at $37,000. BNP Paribas Financial Markets acquired a new position in CeriBell during the fourth quarter valued at $43,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in CeriBell during the 1st quarter worth about $36,000.
About CeriBell
(
Get Free Report)
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Further Reading

Before you consider CeriBell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CeriBell wasn't on the list.
While CeriBell currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.